Publications by authors named "T R Crosby"

Importance: Airway stenosis is a rare but debilitating disorder that significantly degrades the quality of life in affected patients. Treatments are primarily surgical, and disease management lacks established medical therapies. The North American Airway Collaborative held its third symposium at The Johns Hopkins Hospital in Baltimore, Maryland, on April 15, 2024, focused on strategies to advance the care of these patients.

View Article and Find Full Text PDF

Aims: The SCOPE2 trial evaluates radiotherapy (RT) dose escalation for oesophageal cancer. We report findings from the accompanying RT quality assurance (RTQA) programme and identify recommendations for PROTIEUS, the next UK trial in oesophageal RT.

Maetrials And Methods: SCOPE2's RTQA programme consisted of a pre-accrual and on-trial component.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to establish epidemiological cut-off values for the minimum inhibitory concentrations (MICs) of 10 antimicrobial agents against the bacteria Vibrio parahaemolyticus using standardized testing methods.
  • Eight laboratories conducted broth microdilution tests at two different temperatures (35°C and 28°C) to assess the effect of incubation temperature on MIC values, finding that many values were consistent across both temperatures.
  • The generated data will be submitted to the Clinical and Laboratory Standards Institute to help set international standards for interpreting antimicrobial susceptibility tests for this species.
View Article and Find Full Text PDF

Aims: The role of radiotherapy (RT) for inoperable gastric cancer (IGC) is commonly low-dose, given reactively for symptoms (e.g. bleeding), in contrast to the oesophagus, where high quality evidence exists for higher doses of RT.

View Article and Find Full Text PDF

Purpose: The ESPAC4 trial showed that adjuvant chemotherapy with gemcitabine plus capecitabine (GemCap) produced longer overall survival (OS) than gemcitabine monotherapy. Subsequently, the PRODIGE24-CCTG PA.6 trial showed even longer survival for modified fluorouracil, folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) than gemcitabine but had more restrictive eligibility criteria.

View Article and Find Full Text PDF